Contact
searchSearch
HMP Global

Health Care Policy and Legislation

Conference Coverage
MFN Pricing, IRA Negotiation, PBM Scrutiny, and 340B Remain Top Market Access Concerns
04/29/2026
Danielle Sposato
At Asembia 2026, market access leaders warned that sweeping policy shifts—from most favored nation (MFN) pricing and Inflation Reduction Act (IRA) negotiations to pharmacy benefit manager (PBM) and 340B reform—are reshaping global pricing...
At Asembia 2026, market access leaders warned that sweeping policy shifts—from most favored nation (MFN) pricing and Inflation Reduction Act (IRA) negotiations to pharmacy benefit manager (PBM) and 340B reform—are reshaping global pricing...
At Asembia 2026, market access...
04/29/2026
First Report Managed Care
Conference Coverage
IRA, MFN Pressure, and Coverage Volatility Are Reshaping Specialty Drug Access
04/28/2026
Danielle Sposato
At Asembia 2026, Dee Chaudhary, Principal, Commercial Strategy Consulting Life Sciences and Healthcare, Clarivate, outlined how the Inflation Reduction Act (IRA), renewed Most Favored Nation (MFN)-style pricing pressure, and broader coverage...
At Asembia 2026, Dee Chaudhary, Principal, Commercial Strategy Consulting Life Sciences and Healthcare, Clarivate, outlined how the Inflation Reduction Act (IRA), renewed Most Favored Nation (MFN)-style pricing pressure, and broader coverage...
At Asembia 2026, Dee Chaudhary,...
04/28/2026
First Report Managed Care
Conference Coverage
PBM Reform, Drug Pricing Policy, and Regulatory Uncertainty
04/28/2026
Danielle Sposato
As the 2026 midterm elections approach, the health policy landscape faces major uncertainty. This panel will explore how potential changes to congressional power-balance and state dynamics could shape key priorities like drug pricing,...
As the 2026 midterm elections approach, the health policy landscape faces major uncertainty. This panel will explore how potential changes to congressional power-balance and state dynamics could shape key priorities like drug pricing,...
As the 2026 midterm elections...
04/28/2026
First Report Managed Care
News
Trump Administration Announces 17th Most-Favored-Nation Drug Pricing Agreement With Regeneron
04/23/2026
Danielle Sposato
The Trump Administration today announced a new agreement with pharmaceutical manufacturer Regeneron aimed at aligning US prescription drug prices with those paid in other developed nations under a most-favored-nation (MFN) pricing model.
The Trump Administration today announced a new agreement with pharmaceutical manufacturer Regeneron aimed at aligning US prescription drug prices with those paid in other developed nations under a most-favored-nation (MFN) pricing model.
The Trump Administration today...
04/23/2026
First Report Managed Care
News
Trump Administration Announces 17th Most-Favored-Nation Drug Pricing Agreement With Regeneron
04/23/2026
Danielle Sposato
The Trump Administration today announced a new agreement with pharmaceutical manufacturer Regeneron aimed at aligning US prescription drug prices with those paid in other developed nations under a most-favored-nation (MFN) pricing model.
The Trump Administration today announced a new agreement with pharmaceutical manufacturer Regeneron aimed at aligning US prescription drug prices with those paid in other developed nations under a most-favored-nation (MFN) pricing model.
The Trump Administration today...
04/23/2026
First Report Managed Care
Conference Coverage
Federal Drug Pricing, Medicaid Policy, and PBM Reforms Shape 2026 Health Care Landscape
04/14/2026
Grace Taylor, MS, MA
A session at the annual AMCP conference unpacked the latest federal legislative and regulatory changes impacting drug pricing, Medicaid policy, and payer operations in a rapidly shifting environment.
A session at the annual AMCP conference unpacked the latest federal legislative and regulatory changes impacting drug pricing, Medicaid policy, and payer operations in a rapidly shifting environment.
A session at the annual AMCP...
04/14/2026
First Report Managed Care
News
Trump Administration Announces Tariffs on Patented Pharmaceuticals Under Section 232
04/02/2026
Danielle Sposato
April 2, 2026 — Washington, D.C. — The Trump administration has announced new tariffs on imported patented pharmaceutical products and their ingredients under Section 232 of the Trade Expansion Act of 1962, citing national security and supply...
April 2, 2026 — Washington, D.C. — The Trump administration has announced new tariffs on imported patented pharmaceutical products and their ingredients under Section 232 of the Trade Expansion Act of 1962, citing national security and supply...
April 2, 2026 — Washington, D.C....
04/02/2026
First Report Managed Care
News
Aetna Reaches $117.7M Settlement in False Claims Act Violation
03/11/2026
Danielle Sposato
Aetna Inc. has agreed to pay $117.7 million to resolve allegations that it violated the False Claims Act by submitting or failing to withdraw inaccurate diagnosis codes for Medicare Advantage (MA) enrollees, resulting in inflated payments...
Aetna Inc. has agreed to pay $117.7 million to resolve allegations that it violated the False Claims Act by submitting or failing to withdraw inaccurate diagnosis codes for Medicare Advantage (MA) enrollees, resulting in inflated payments...
Aetna Inc. has agreed to pay...
03/11/2026
First Report Managed Care
News
TrumpRx.gov Launch Targets Lower Prescription Drug Prices in United States
02/06/2026
Juliet Gallagher
The Trump Administration has announced the launch of TrumpRx.gov, a new website designed to provide American patients with access to prescription drug prices aligned with the lowest paid in other developed nations. The initiative applies...
The Trump Administration has announced the launch of TrumpRx.gov, a new website designed to provide American patients with access to prescription drug prices aligned with the lowest paid in other developed nations. The initiative applies...
The Trump Administration has...
02/06/2026
First Report Managed Care
Yuri Fesko, MD, PAMA, Health Care Policy, Medicare
Interview
PAMA and the Downstream Impact of Lab Reimbursement on Cancer Care Access
01/22/2026
Yuri Fesko, MD
In this interview, senior vice president and chief medical officer at Quest Diagnostics, Yuri Fesko, MD, discusses how Medicare laboratory reimbursement under PAMA threatens access to precision cancer diagnostics—particularly for rural and...
In this interview, senior vice president and chief medical officer at Quest Diagnostics, Yuri Fesko, MD, discusses how Medicare laboratory reimbursement under PAMA threatens access to precision cancer diagnostics—particularly for rural and...
In this interview, senior vice...
01/22/2026
First Report Managed Care

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use